Holen Sie sich die Stockscreener-App
32.65
0.28%
0.09
Handel nachbörslich:
32.85
0.20
+0.61%
Schlusskurs vom Vortag:
$32.56
Offen:
$32.94
24-Stunden-Volumen:
4.36M
Relative Volume:
1.00
Marktkapitalisierung:
$3.64B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-99.15M
KGV:
-35.11
EPS:
-0.93
Netto-Cashflow:
$-74.25M
1W Leistung:
-16.94%
1M Leistung:
-30.09%
6M Leistung:
-34.49%
1J Leistung:
+52.43%
1-Tages-Spanne:
$32.56
$34.24
1-Wochen-Bereich:
$32.51
$39.40
52-Wochen-Spanne:
$20.47
$99.41
Viking Therapeutics Inc Stock (VKTX) Company Profile
Firmenname
Viking Therapeutics Inc
Sektor
Branche
Telefon
858-704-4660
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Vergleichen Sie VKTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
32.65 | 3.64B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-22 | Eingeleitet | B. Riley Securities | Buy |
| 2024-11-04 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-11 | Eingeleitet | JP Morgan | Overweight |
| 2024-06-27 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-07 | Eingeleitet | Jefferies | Buy |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2023-05-31 | Fortgesetzt | ROTH MKM | Buy |
| 2023-03-28 | Bestätigt | Maxim Group | Buy |
| 2023-03-17 | Eingeleitet | Stifel | Buy |
| 2021-07-29 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-05-01 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-25 | Eingeleitet | Stifel | Buy |
| 2019-03-29 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Bestätigt | Maxim Group | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-18 | Bestätigt | Maxim Group | Buy |
| 2018-09-18 | Bestätigt | Raymond James | Outperform |
| 2018-07-20 | Eingeleitet | SunTrust | Buy |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-01 | Bestätigt | Laidlaw | Buy |
| 2018-05-31 | Bestätigt | Maxim Group | Buy |
| 2018-03-26 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | Maxim Group | Buy |
| 2017-11-21 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
Viking Therapeutics: The Turning Point Is Not Here Yet - Seeking Alpha
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views? - Zacks Investment Research
Why Viking Therapeutics, Inc. (VKTX) Crashed Last Week - MSN
These 10 Firms Were Last Week’s Worst Performers - Insider Monkey
Viking Therapeutics (NASDAQ:VKTX) Shares Down 4.8%Here's Why - MarketBeat
Shelton Wealth Management LLC Purchases New Stake in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Receives "Buy" Rating from HC Wainwright - MarketBeat
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
Viking Therapeutics (NASDAQ:VKTX) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today - sharewise
Viking Therapeutics (NASDAQ:VKTX) Trading Down 4.8%Here's What Happened - MarketBeat
Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs - AOL
Why Viking Therapeutics (VKTX) Is the Biotech Stock with Biggest Upside Potential - MSN
We Asked Retail How Viking Therapeutics Can Restore Investor Confidence: Majority Say Pursue Buyout Talks - MSN
Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today - Benzinga
NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down - Yahoo Finance
Viking Therapeutics posts positive results for oral weight-loss drug. Analysts remain unanimous the stock’s a buy. - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc.VKTX - PR Newswire
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday - MSN
Viking Therapeutics Becomes Oversold (VKTX) - Nasdaq
Viking Therapeutics, Inc. (VKTX) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
Viking Therapeutics’ oral-2735 could differentiate asset, says JPMorgan - MSN
International Assets Investment Management LLC Reduces Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX) - MarketBeat
Viking Therapeutics begins VK2735 Phase II trial for obesity treatment - Yahoo Finance
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug - Yahoo Finance
Viking Therapeutics begins phase 2 trial for obesity drug By Investing.com - Investing.com Nigeria
Should You Buy the Dip on This High-Flying Stock? - AOL
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - The Malaysian Reserve
Viking Therapeutics (NASDAQ:VKTX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral - GuruFocus.com
Viking Therapeutics begins phase 2 trial for obesity drug - Investing.com
Viking Therapeutics Launches Phase 2 Trial for Oral Weight Loss Drug After Impressive Early Results - StockTitan
Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - Kilgore News Herald
Viking Therapeutics COO sells $2.3 million in stock By Investing.com - Investing.com South Africa
Viking therapeutics CEO sells $8.3 million in stock - Investing.com India
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Insider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) CFO Sells 50,309 Shares of Stock - MarketBeat
Insider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) COO Sells 54,215 Shares of Stock - MarketBeat
Viking therapeutics CEO sells $8.3 million in stock By Investing.com - Investing.com Nigeria
Viking Therapeutics CFO sells shares worth $2.15 million By Investing.com - Investing.com Nigeria
Viking Therapeutics COO sells $2.3 million in stock - Investing.com
VKTXViking Therapeutics, Inc Latest Stock News & Market Updates - StockTitan
President & CEO Lian Brian was granted 256,133 shares and sold $8,313,601 worth of shares (194,490 units at $42.75), increasing direct ownership by 3% to 2,366,570 units (SEC Form 4) - Quantisnow
Chief Operating Officer Mancini Marianna was granted 66,200 shares and sold $2,317,599 worth of shares (54,215 units at $42.75), increasing direct ownership by 3% to 374,134 units (SEC Form 4) - Quantisnow
Chief Financial Officer Zante Greg sold $2,150,595 worth of shares (50,309 units at $42.75) and was granted 66,200 shares, increasing direct ownership by 11% to 165,259 units (SEC Form 4) - Quantisnow
SEC Form 4 filed by Director Macartney Lawson - Quantisnow
1 Under-the-Radar Stock to Buy Before It Soars by 156%, According to Select Wall Street Analysts - The Motley Fool
Higher Biopharma M&A Activity ‘Almost Inevitable’ in 2025, With Viking as Top Candidate: Analysts - BioSpace
Viking Therapeutics, Inc. (NASDAQ:VKTX) CEO Brian Lian Sells 194,490 Shares - MarketBeat
SA Asks: Which biotechs are most likely to be acquired near-term? - Seeking Alpha
Why Viking Therapeutics Stock Plummeted by 24% in December - MSN
Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
4.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):